JP6542222B2 - ベンゾキノリン化合物の製造方法 - Google Patents

ベンゾキノリン化合物の製造方法 Download PDF

Info

Publication number
JP6542222B2
JP6542222B2 JP2016536571A JP2016536571A JP6542222B2 JP 6542222 B2 JP6542222 B2 JP 6542222B2 JP 2016536571 A JP2016536571 A JP 2016536571A JP 2016536571 A JP2016536571 A JP 2016536571A JP 6542222 B2 JP6542222 B2 JP 6542222B2
Authority
JP
Japan
Prior art keywords
certain embodiments
acid
compound
water
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016536571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501141A5 (enExample
JP2017501141A (ja
Inventor
チェンジ・ジャン
Original Assignee
オースペックス ファーマシューティカルズ インコーポレイテッド
オースペックス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オースペックス ファーマシューティカルズ インコーポレイテッド, オースペックス ファーマシューティカルズ インコーポレイテッド filed Critical オースペックス ファーマシューティカルズ インコーポレイテッド
Publication of JP2017501141A publication Critical patent/JP2017501141A/ja
Publication of JP2017501141A5 publication Critical patent/JP2017501141A5/ja
Application granted granted Critical
Publication of JP6542222B2 publication Critical patent/JP6542222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
    • C07C223/02—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2016536571A 2013-12-03 2014-11-24 ベンゾキノリン化合物の製造方法 Active JP6542222B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911214P 2013-12-03 2013-12-03
US61/911,214 2013-12-03
PCT/US2014/067117 WO2015084622A1 (en) 2013-12-03 2014-11-24 Methods of manufacturing benzoquinoline compounds

Publications (3)

Publication Number Publication Date
JP2017501141A JP2017501141A (ja) 2017-01-12
JP2017501141A5 JP2017501141A5 (enExample) 2018-01-11
JP6542222B2 true JP6542222B2 (ja) 2019-07-10

Family

ID=53264424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536571A Active JP6542222B2 (ja) 2013-12-03 2014-11-24 ベンゾキノリン化合物の製造方法

Country Status (14)

Country Link
US (8) US20150152099A1 (enExample)
EP (2) EP3424504A1 (enExample)
JP (1) JP6542222B2 (enExample)
KR (1) KR102391134B1 (enExample)
CN (1) CN105873589B (enExample)
AU (4) AU2014357518A1 (enExample)
BR (1) BR112016012747B1 (enExample)
CA (1) CA2930744A1 (enExample)
EA (2) EA032920B1 (enExample)
HK (1) HK1224222A1 (enExample)
IL (1) IL245539B (enExample)
MX (1) MX369956B (enExample)
NZ (1) NZ720301A (enExample)
WO (1) WO2015084622A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
NZ720301A (en) 2013-12-03 2022-01-28 Auspex Pharmaceuticals Inc Deuterated tetrabenazine compounds
EP4140483A1 (en) 2015-03-06 2023-03-01 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
WO2017182916A1 (en) 2016-04-22 2017-10-26 Lupin Limited Novel process for preparation of tetrabenazine and deutetrabenazine
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
EP3585787A1 (en) 2017-02-27 2020-01-01 Sandoz AG Crystalline forms of valbenazine salts
TWI772382B (zh) * 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途
WO2019130252A2 (en) * 2017-12-29 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing deutetrabenazine
US11505549B2 (en) * 2018-02-01 2022-11-22 Lakshmi Prasad ALAPARTHI Process for preparation of Deutetrabenazine
SG11202103726RA (en) 2018-10-18 2021-05-28 Oncopeptides Ab Compounds containing deuterium
TW202033521A (zh) * 2018-10-24 2020-09-16 美商紐羅克里生物科學有限公司 製備囊泡單胺轉運蛋白2(vmat2)抑制劑之方法
CN111960999B (zh) * 2020-07-20 2021-11-02 暨明医药科技（苏州）有限公司 一种丁苯那嗪中间体的合成方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) 1958-07-15 Method for preparing same
US2830993A (en) 1958-04-15 Quinolizine derivatives
US2326643A (en) 1941-08-20 1943-08-10 Rohm & Haas Complex polyamino sulphur compound
US3045021A (en) 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999095A (en) * 1961-02-21 1965-07-21 Wellcome Found The preparation of quinolizine derivatives
HU175890B (en) 1977-06-15 1980-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new 1,2,3,4,6,7-hexahydro-11-b-alpha-benzo-square bracket-a-square brecket closed-quinolyzine derivatives
US4316897A (en) 1980-09-10 1982-02-23 Hoffmann-La Roche Inc. Method of lowering serum prolactin
DE3407955A1 (de) 1984-03-03 1985-09-05 Dr. Karl Thomae Gmbh, 7950 Biberach Arzneimittel, enthaltend quartaere 3,4-dihydroisochinoliniumsalze
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
GB9817028D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
EP1134290A3 (en) 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
PL1638529T3 (pl) 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
EP1684806B1 (en) 2003-11-21 2008-06-25 Memory Pharmaceuticals Corporation Compositions comprising l-type calcium channel blockers and cholinesterase inhibitors
US7367953B2 (en) 2003-11-26 2008-05-06 Ge Medical Systems Global Technology Company Method and system for determining a period of interest using multiple inputs
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
DK1856135T3 (da) 2005-01-19 2010-04-12 Rigel Pharmaceuticals Inc Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser
EP1901720A2 (en) 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20080033011A1 (en) 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
EP3101001B1 (en) 2006-02-17 2020-04-01 Teva Pharmaceuticals International GmbH Deuterated catecholamine derivatives and medicaments comprising said compounds
DK2012833T3 (en) 2006-05-02 2015-01-19 Univ Pennsylvania RADIOACTIVALLY LABELED DIHYDROTETRABENAZINE DERIVATIVES AND USE THEREOF AS IMAGING AGENTS
HU227610B1 (en) 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
CN101557819A (zh) 2006-10-12 2009-10-14 诺瓦提斯公司 修饰的环孢素的用途
ES2402220T3 (es) 2006-11-08 2013-04-29 Neurocrine Biosciences, Inc. Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos
JP5264759B2 (ja) 2006-11-21 2013-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用
US20100204258A1 (en) 2007-03-12 2010-08-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
US7897768B2 (en) 2007-06-08 2011-03-01 General Electric Company Method for making tetrabenazine compounds
EP2173344B1 (en) 2007-06-29 2016-04-06 Clarencew Pty Ltd. Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
US7902364B2 (en) 2007-11-29 2011-03-08 General Electric Company Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
WO2009124357A1 (en) 2008-04-10 2009-10-15 Malvin Leonard Eutick Fast dissolving oral formulations for critical drugs
US9012471B2 (en) 2008-04-11 2015-04-21 The Trustees Of Columbia University In The City Of New York Glucose metabolism modulating compounds
CN201204923Y (zh) 2008-04-14 2009-03-11 云南省烟草公司昆明市公司 鲜烟叶编叶机
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
DE102008040212A1 (de) 2008-07-07 2010-01-14 Zf Friedrichshafen Ag Radaufhängung für ein Fahrzeug
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
CN104311552A (zh) 2008-09-18 2015-01-28 奥斯拜客斯制药有限公司 囊泡单胺转运体2 的苯并喹啉抑制剂
US20100113496A1 (en) 2008-09-25 2010-05-06 Auspex Pharmaceuticals, Inc. Piperidine modulators of vmat2
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
CA2771539A1 (en) 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
JP4679658B2 (ja) 2009-10-10 2011-04-27 株式会社オーバル フィールド機器の光電センシング感度調整
CN102120742B (zh) 2010-01-08 2013-03-13 中国药科大学 一种丁苯那嗪的制备方法
AU2011218805A1 (en) 2010-02-24 2012-08-30 Auspex Pharmaceuticals, Inc. Trimethoxyphenyl inhibitors of tyrosine kinase
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
EP3351247A1 (en) 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012006551A2 (en) 2010-07-08 2012-01-12 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
CN102260255B (zh) 2011-07-07 2013-07-10 江苏省原子医学研究所 一种9,10-二甲氧基-1,3,4,6,7,11b-六氢-3-异丁基-2H-苯并[a]喹嗪-2-酮的简便合成方法
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
KR101362482B1 (ko) 2012-01-31 2014-02-12 한국과학기술연구원 테트라베나진과 다이하이드로테트라베나진의 제조방법
EP3884937A1 (en) 2012-03-23 2021-09-29 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN102936246A (zh) * 2012-11-08 2013-02-20 江苏暨明医药科技有限公司 丁苯那嗪的合成方法
EP2951178A4 (en) 2013-01-31 2016-07-06 Auspex Pharmaceuticals Inc VMAT2 INHIBITORS OF BENZOQUINOLONE TYPE
CA2925562A1 (en) 2013-09-27 2015-04-02 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
HK1224294A1 (zh) 2013-11-22 2017-08-18 Auspex Pharmaceuticals, Inc. 治疗异常肌肉活动的方法
WO2015077521A1 (en) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
NZ720301A (en) 2013-12-03 2022-01-28 Auspex Pharmaceuticals Inc Deuterated tetrabenazine compounds
EP3398602A1 (en) 2014-01-27 2018-11-07 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2

Also Published As

Publication number Publication date
AU2023203246A1 (en) 2023-06-15
HK1223020A1 (zh) 2017-07-21
HK1224222A1 (zh) 2017-08-18
EP3076970A1 (en) 2016-10-12
CN105873589A (zh) 2016-08-17
US20180230083A1 (en) 2018-08-16
US20200347008A1 (en) 2020-11-05
EA201691162A1 (ru) 2016-11-30
EA201791466A1 (ru) 2017-11-30
AU2023203246B2 (en) 2025-02-27
MX2016007056A (es) 2017-01-06
IL245539A0 (en) 2016-06-30
MX369956B (es) 2019-11-27
CA2930744A1 (en) 2015-06-11
WO2015084622A1 (en) 2015-06-11
AU2014357518A1 (en) 2016-06-09
AU2020201091A1 (en) 2020-03-05
EA032920B1 (ru) 2019-08-30
AU2020201091B2 (en) 2021-04-29
AU2021209150A1 (en) 2021-08-19
US20170197957A1 (en) 2017-07-13
EP3424504A1 (en) 2019-01-09
IL245539B (en) 2021-06-30
US20150152099A1 (en) 2015-06-04
US10513488B2 (en) 2019-12-24
BR112016012747B1 (pt) 2022-07-12
US20230060294A1 (en) 2023-03-02
NZ720301A (en) 2022-01-28
KR102391134B1 (ko) 2022-04-28
KR20160087904A (ko) 2016-07-22
US20200331846A1 (en) 2020-10-22
EP3076970A4 (en) 2017-07-26
JP2017501141A (ja) 2017-01-12
CN105873589B (zh) 2019-11-01
US12077487B2 (en) 2024-09-03
US20190092719A1 (en) 2019-03-28
BR112016012747A2 (enExample) 2017-08-08
US20170190654A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
JP6542222B2 (ja) ベンゾキノリン化合物の製造方法
JP2015063529A (ja) アルホルモテロールの合成方法
JPH10504820A (ja) Ｎ−置換されたフェノチアジン類の使用
EP3100735A1 (en) Crystalline fosaprepitant dicyclohexylamine salt and its preparation
CN101985447A (zh) 丁苯那嗪的拆分方法
JP7748560B2 (ja) ピラゾロ縮合環化合物及びその使用
HK1223020B (zh) 制造苯并喹啉化合物的方法
ES2267399B1 (es) Procedimiento para la obtencion de carbamatos de fenilo.
US10131624B2 (en) Process for the preparation of (1S,2R)-Milnacipran
JP2013529687A (ja) キナーゼインヒビターの合成および使用
MXPA96006100A (en) Asymmetric synthesis of substitute methanamins with alpha-cyclal
RU2537361C1 (ru) Оптические изомеры (+) и (-)-бензгидрилмочевин и (+) и (-)-1-[(3-хлорфенил)-фенил-метил]мочевины, фармацевтическая композиция на их основе и способ их получения
EP2348013A1 (en) Process for preparation of intermediates of arformoterol
MXPA02008538A (es) Procedimiento para la preparacion de compuestos de 2-(4-alquil-1-piperacinil)-benzaldehido y -bencilidenilo.
JPH09268162A (ja) イソプレン誘導体
CN111285867A (zh) 一种苯并喹嗪类衍生物的制备方法
US20190194122A1 (en) Processes for the Preparation of Dasotraline and Intermediates Thereof
MXPA99010525A (en) 4-[(aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180806

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190612

R150 Certificate of patent or registration of utility model

Ref document number: 6542222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250